Sistema de Diagnóstico e Monitorização Baseado em Biomarcadores Urinários para Doença Renal Crónica e Eficácia no Mundo Real dos Inibidores de SGLT2
Sistema de Diagnóstico e Monitorização para Doença Renal Crónica Baseado em Biomarcadores Urinários e Tratamento Preventivo com o Inibidor SGLT2 Empagliflozina
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.
The project integrates translational and clinical components:
- validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
- evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.
A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.
The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.
Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.
The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Carlos Martínez Salgado, PhD
- Número de telefone: +34616129633
- E-mail: carlosms@usal.es
Locais de estudo
-
-
-
Salamanca, Espanha
- Recrutamento
- Hospital Universitario de Salamanca
-
Contato:
- Carlos Martínez Salgado, PhD
- Número de telefone: +34616129633
- E-mail: carlosms@usal.es
-
Contato:
- Pilar Fraile Gómez, MD, PhD
- Número de telefone: +34923291100
- E-mail: pilarfg@usal.es
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants with chronic kidney disease (CKD) stages 2-4.
Descrição
Inclusion Criteria:
- ≥18 years old
- Diagnosed with chronic kidney disease (KDIGO stages 2-4)
- Life expectancy ≥12 months
- Available clinical and laboratory data in the electronic medical record
Exclusion Criteria:
- Current or recent renal replacement therapy or kidney transplantation
- End-stage renal disease
- Participation in interventional trials that may affect outcomes
- Allergy or intolerance to SGLT2i (for exposed cohort)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Empagliflozin Treatment Group
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety. |
Oral empagliflozin (10-25 mg daily) for 12 months |
|
Control group
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over). |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in urinary biomarker panel expression (proteomic fingerprint)
Prazo: Baseline, 6 months, 12 months
|
Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels. |
Baseline, 6 months, 12 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR)
Prazo: Baseline, 6 months, 12 months
|
Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment. |
Baseline, 6 months, 12 months
|
|
Histopathological improvement of renal tissue (animal study)
Prazo: Monthly up to 9 months
|
Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin. |
Monthly up to 9 months
|
|
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Prazo: From baseline to 12 months
|
Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator. |
From baseline to 12 months
|
|
Change in estimated glomerular filtration rate (eGFR)
Prazo: From baseline to 12 months
|
Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation. |
From baseline to 12 months
|
|
Change in serum creatinine
Prazo: From baselinte to 12 months
|
hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL). |
From baselinte to 12 months
|
|
Change in urinary albumin-to-creatinine ratio
Prazo: From baseline to 12 months
|
Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine). |
From baseline to 12 months
|
|
Change in serum electrolyte levels
Prazo: From baseline to 12 months
|
Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L). |
From baseline to 12 months
|
|
Change in liver function tests
Prazo: From baseline to 12 months
|
Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L). |
From baseline to 12 months
|
|
Change in glycated hemoglobin (HbA1c)
Prazo: From baseline to 12 months.
|
Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%). |
From baseline to 12 months.
|
|
Change in hematological parameters
Prazo: From baseline to 12 months
|
Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing. |
From baseline to 12 months
|
|
Change in blood pressure
Prazo: From baseline to 12 months
|
Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg). |
From baseline to 12 months
|
|
Change in body weight
Prazo: From baseline to 12 months
|
Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg). |
From baseline to 12 months
|
|
Discontinuation due to treatment intolerance
Prazo: From baseline to 12 months
|
Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting. |
From baseline to 12 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Carlos Martínez Salgado, PhD, University of Salamanca
- Investigador principal: Pilar Fraile Gómez, MD, PhD, University of Salamanca
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Insuficiência renal
- Condições Patológicas, Sinais e Sintomas
- Insuficiência Renal Crônica
- Empagliflozina
Outros números de identificação do estudo
Outros números de identificação do estudo
- PI25/00053
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Prazo de Compartilhamento de IPD
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
Critérios de acesso de compartilhamento IPD
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .